Superworth

GT Biopharma EPS GTBP

Diluted earnings per share by quarter and over the last twelve months, from 2010.

Last 12 months, to Jun 30, 2026
$5.75
Latest quarter, Q2 FY26
−$3.00
Fiscal year 2025
−$269.75

GT Biopharma's earnings per share was $5.75 over the twelve months to Jun 30, 2026.

In its latest quarter, Q2 FY26, it was −$3.00.

Earnings per share over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearEPSChange
FY2025−$269.75n/a
FY2024−$175.25n/a
FY2023−$140.25n/a
FY2022n/an/a
FY2020−$6277.50n/a
FY2019−$8542.50n/a
FY2018−$65790.00−100%
FY2017$6107484217.50n/a
FY2016−$369367.50n/a
FY2014−$39703500.00n/a
FY2013$0.00n/a
FY2012−$9562500.00n/a
FY2011−$9562500.00n/a
FY2010n/an/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedEPSOn a year earlierLast 12 months
Q2 FY26−$3.00n/a$5.75
Q1 FY26−$2.75n/a−$264.25
Q4 FY25−$14.50n/a−$269.75
Q3 FY25$26.00n/a−$297.00
Q2 FY25−$273.00n/a−$361.25
Q1 FY25−$8.25n/a−$142.50
Q4 FY24−$41.75n/a−$175.25
Q3 FY24−$38.25n/a−$187.00
Q2 FY24−$54.25n/a−$193.00
Q1 FY24−$41.00n/a−$176.00
Q4 FY23−$53.50n/a−$140.25
Q3 FY23−$44.25n/a−$216.50

Against its peers

Companies in Drug Manufacturers - General nearest GT Biopharma's size, closest first, today.

CompanyEPS, 12 monthsGrowth
GTBPGT Biopharma$5.75
ATNMActinium Pharmaceuticals$0.36
SPROSpero Therapeutics$0.11
LFVNLifevantage$0.40−46% a year
Peer median$0.36

What the EPS figure tells you

Net income divided by diluted shares. The denominator of PE.

One-off charges and gains swing it. The TTM view smooths a single odd quarter.

More on GT Biopharma

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.